Corrigendum to “A narrative review of approved and emerging anti-obesity medications” [Saudi Pharm. J. 31(10) (2023) 101757]
Semira Abdi Beshir,
Asim Ahmed Elnour,
Aadith Soorya,
Affana Parveen Mohamed,
Sheron Sir Loon Goh,
Nadia Hussain,
Amal H.I. Al Haddad,
Faizah Hussain,
Israa Yousif EL Khidir,
Zainab Abdelnassir
Affiliations
Semira Abdi Beshir
Department of clinical pharmacy and Pharmacotherapeutics, Dubai Pharmacy College For Girls, Dubai, United Arab Emirates
Asim Ahmed Elnour
Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Abu Dhabi Campus, United Arab Emirates; AAU Health and Biomedical Research Centre, Al Ain University, Abu Dhabi, United Arab Emirates; Corresponding author at: Program of Clinical Pharmacy, College of Pharmacy, Al Ain University (AAU), Abu Dhabi campus, Abu Dhabi, United Arab Emirates; AAU Health and Biomedical Research Centre, Al Ain University, Abu Dhabi-United Arab Emirates.
Aadith Soorya
College of Medicine, Gulf Medical University, Ajman, United Arab Emirates
Affana Parveen Mohamed
College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates
Sheron Sir Loon Goh
Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Nadia Hussain
Department of Pharmaceutical Sciences, College of Pharmacy, 105949, Al Ain University, Al Ain, United Arab Emirates; AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates
Amal H.I. Al Haddad
Chief Operation Officer, Sheikh Shakhbout Medical City (SSMC), Abu Dhabi, United Arab Emirates
Faizah Hussain
Department of clinical pharmacy and Therapeutics, Dubai Pharmacy College, Dubai, United Arab Emirates
Israa Yousif EL Khidir
Department of Clinical Pharmacy and Pharmacy Practice, (PhD, MSc, B Pharm), College of Pharmacy, Najran University, Najran -King Saudi Arabia (KSA), Saudi Arabia
Zainab Abdelnassir
Fourth-year pharmacy, Abu Dhabi, United Arab Emirates; College of Pharmacy, Al Ain University, Abu Dhabi Campus, United Arab Emirates